[Induction chemotherapy for solid tumors]

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Context:

• Surgical treatment is the gold standard for operable solid tumors.
• Advanced cancers often require multimodality regimens integrating surgery with nonsurgical treatments.
• The sequence and timing of combined therapies are critical for treatment efficacy.

Purpose:

• To explore the role and efficacy of induction chemotherapy as a component of primary treatment for solid malignancies.
• To evaluate the impact of induction chemotherapy on tumor downstaging, surgical outcomes, and disease recurrence.
• To discuss the advantages, disadvantages, and future directions of induction chemotherapy strategies.

Summary:

• Induction chemotherapy, administered before definitive treatment, aims to reduce distant disease recurrence and improve surgical outcomes.
• It can lead to tumor downstaging, enabling conservative surgery or making inoperable tumors resectable.
• While systemic induction chemotherapy is used for stages II/III disease, its significant improvement in disease-free survival (DFS) or overall survival (OS) is not consistently proven, though pathological complete response (pCR) shows favorable effects.

Impact:

• Induction chemotherapy can decrease metastatic disease incidence and potentially improve surgical success rates.
• Further research is needed to identify predictive markers for personalized therapy and develop novel agents for residual disease.
• Understanding the optimal sequencing and timing of induction chemotherapy is essential for maximizing patient benefit and minimizing side effects.